Story perspectives

Setidegrasib Shows Promise for KRAS G12D-Mutant Cancers

4/9/2026

Summary

Story summary

A phase I trial of setidegrasib, a first-in-class KRAS G12D-targeted protein degrader, shows encouraging activity in patients with advanced KRAS G12D-mutant cancers.
Among 203 participants, 36% of non-small cell lung cancer (NSCLC) patients responded to setidegrasib.
The median progression-free survival was 8.3 months.
The drug demonstrated a manageable toxicity profile, with most adverse events mild.
Experts believe combining these KRAS-targeted drugs could enhance treatment for KRAS-mutant cancers.

1 of 1

Story summary

A phase I trial of setidegrasib, a first-in-class KRAS G12D-targeted protein degrader, shows encouraging activity in patients with advanced KRAS G12D-mutant cancers.
Among 203 participants, 36% of non-small cell lung cancer (NSCLC) patients responded to setidegrasib.
The median progression-free survival was 8.3 months.
The drug demonstrated a manageable toxicity profile, with most adverse events mild.
Experts believe combining these KRAS-targeted drugs could enhance treatment for KRAS-mutant cancers.